PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Light to Heal Unhealable Foot Wounds: A New Gel Therapy for Diabetic Foot Ulcers

If you live with diabetes, you likely know the long list of potential health complications that come with unregulated blood sugar: eye damage, kidney strain, heart trouble, and nerve loss. Yet one of the most feared, underdiscussed complications sits right at your feet: diabetic foot ulcers (DFUs). These open, slow-healing sores do not just cause persistent discomfort—they carry devastating long-term risks, including life-threatening infections and lower-limb amputation. Worldwide, millions of adults living with diabetes battle chronic foot ulcers each year, and standard wound care often fails to close stubborn wounds that linger for months or even years.

For decades, doctors have relied on consistent wound cleaning, dead tissue removal, antibiotics, and pressure relief to treat DFUs. While these “standard-of-care” measures prevent worsening damage, they lack a powerful, targeted tool to eliminate hidden bacteria, speed tissue regrowth, and cut amputation odds long-term. Today, a promising experimental treatment combining a light-activated gel and low-intensity red laser light is being tested in a global clinical trial to fill this critical gap: Chlorin E6 gel photodynamic therapy, or Ce6-PDT.

This article breaks down everything everyday readers need to understand: why diabetic foot ulcers form and why they are so dangerous, how photodynamic therapy works in plain language, what the new Chlorin E6 gel treatment entails, details of the ongoing Phase IIb/III clinical trial based at Creek General Hospital in Karachi, Pakistan, and what this research could mean for millions of people living with hard-to-heal foot wounds. Written for non-medical audiences, we skip dense jargon, simplify complex lab processes, and focus on real patient benefits, safety questions, and future hope for diabetes wound care.

Part 1: The Silent Crisis of Diabetic Foot Ulcers
What Exactly Is a Diabetic Foot Ulcer?
A diabetic foot ulcer is an open break in the skin on the foot that refuses to heal within four weeks, unique to people living with chronic high blood sugar. Unlike a minor cut that scabs and closes in days, DFUs develop from two core diabetes-related injuries: nerve damage (neuropathy) and poor blood circulation (peripheral artery disease). Think of your foot as a garden: nerves are your garden’s alarm system, and blood vessels are its water supply. Diabetes breaks both systems.

1. Diabetic Neuropathy (Broken Alarm System)
   Prolonged high glucose slowly damages tiny sensory nerves in the feet. Over time, patients lose the ability to feel pain, heat, sharp objects, or friction from ill-fitting shoes. A pebble inside a shoe, a blister from walking, or a minor scrape can develop into a raw wound—and the person never notices until the sore is large and infected. Many DFU patients first discover their ulcer when they see drainage, swelling, or redness, long after tissue damage began.
2. Peripheral Arterial Disease (Blocked Water Supply)
   High blood sugar inflames and narrows small blood vessels feeding the feet. Healthy wounds heal because blood carries oxygen, immune cells, and nutrients to repair damaged skin. Narrowed arteries drastically cut this supply. Even small wounds cannot access the building blocks needed to close, turning minor injuries into chronic, open ulcers that linger for months.

Most DFUs form on the weight-bearing bottom of the foot, around toes, or over bony protrusions where shoes create constant pressure. The trial we explore focuses specifically on ulcers that have existed for at least four weeks, deep enough to reach muscle tissue, but not yet exposing bone or causing gangrene—some of the most common hard-to-treat DFU cases worldwide.

The Staggering Human Cost of Unmanaged DFUs
Statistics paint a grim picture of untreated or slowly healing diabetic foot ulcers:

• Roughly 19% to 34% of all people with diabetes will develop a foot ulcer in their lifetime.
• 80% of all non-traumatic lower-limb amputations in diabetes patients start with a foot ulcer infection.
• Between 14% and 24% of DFU patients will eventually face an amputation of part or all of their foot or leg.
• After an amputation, five-year mortality rates climb as high as 70%, far exceeding the five-year survival rate for many common cancers.
• More than half of all DFUs develop bacterial infections, and one in five moderate-to-severe infected ulcers leads to limb loss.

Beyond life-or-death risks, DFUs wreck quality of life. Patients face constant pain, foul wound drainage, frequent hospital visits, restricted mobility, expensive daily wound dressings, and isolation from walking, travel, or family activities. Recurrence is another huge burden: roughly two-thirds of patients who heal a DFU will develop a new ulcer within three to five years, creating a lifelong cycle of wound care and anxiety.

Why Standard Wound Care Often Falls Short
Today’s standard-of-care (SOC) DFU treatment relies on four core steps, all included in the clinical trial for comparison against the new gel therapy:

1. Debridement: Doctors cut or scrape away dead, infected tissue from the ulcer bed to clear space for healthy skin to regrow. This process only removes surface bacteria, not microscopic germs hidden deep within wound tissue.
2. Targeted Oral Antibiotics: Providers prescribe antibiotics to fight aerobic gram-positive bacteria (the most common DFU germs), including moxifloxacin, linezolid, and co-amoxiclav. Antibiotics carry two major limitations: they cannot penetrate thick bacterial biofilms that coat chronic ulcers, and overuse fuels antibiotic-resistant superbugs that no medication can kill.
3. Blood Sugar Control: Patients work to lower HbA1c and random blood sugar to stable levels, addressing the root cause of nerve and vessel damage, though this does not speed existing wound closure overnight.
4. Protective Dressings & Pressure Relief: Special footwear, casts, or crutches take weight off the ulcer to prevent further tearing, paired with daily wound cleaning and bandage changes.

While SOC prevents immediate worsening, it lacks a tool to fully wipe out hidden bacteria inside the wound and actively boost tissue regeneration. Many patients follow this routine for months and still see minimal shrinkage in their ulcer size. This gap creates an urgent need for a new, localized treatment that attacks infection at its source and accelerates healing—this is where Chlorin E6 photodynamic therapy enters the picture.

Part 2: Photodynamic Therapy (PDT) and Chlorin E6 Gel
What Is Photodynamic Therapy, in Plain Terms?
Photodynamic therapy, or PDT, is a two-step, non-surgical treatment that uses three harmless natural ingredients: a light-sensitive gel (photosensitizer), red laser light, and oxygen already present in human tissue. Unlike antibiotics that travel through your whole body, PDT acts only exactly where you apply it—directly on the ulcer—with zero widespread systemic side effects. The process works like a targeted “light-activated cleaning bomb” for infected wounds.

Here is the simple step-by-step mechanism, no complex chemistry required:

1. A special gel holding the photosensitizer (Chlorin E6) spreads evenly across the ulcer surface. The gel sticks to bacteria and damaged wound tissue, barely clinging to healthy surrounding skin.
2. The patient waits roughly 30 minutes to let the gel sink deep into every crevice of the ulcer bed, reaching hidden bacterial biofilms antibiotics cannot touch.
3. Clinicians wash away excess gel with saline water, then shine a precise red laser light (660–670 nanometers wavelength) over the entire wound for 11 minutes.
4. The red light “wakes up” the Chlorin E6 molecules. Activated Chlorin E6 reacts with oxygen in the wound to create tiny, short-lived oxygen particles called singlet oxygen. These particles instantly destroy bacterial cell walls, erasing infection without harming healthy human skin cells nearby.
5. Doctors check the wound under UV light to confirm bacterial clearing; if germs remain, they deliver a second 11-minute light session to finish disinfection.

Crucially, PDT does not create antibiotic resistance. It kills bacteria through physical chemical damage to their cell structure, not chemical blocking like antibiotics. Even drug-resistant MRSA and other superbugs cannot evade singlet oxygen destruction, making PDT a game-changer for chronic infected wounds that no pill can fully clear.

What Makes Chlorin E6 the Perfect Photosensitizer for Foot Ulcers?
Chlorin E6 (shortened to Ce6) is a second-generation photosensitizer, refined over older light-activated compounds used in early PDT cancer treatments. It has three key advantages for topical foot wound use:

1. Localized, Low Systemic Absorption: When applied as a gel directly on the ulcer, almost no Chlorin E6 seeps into the bloodstream. Unlike older injected photosensitizers that force patients to avoid sunlight for weeks, this topical gel creates minimal whole-body light sensitivity—an enormous practical benefit for everyday patients.
2. Powerful Singlet Oxygen Production: Ce6 generates far more germ-killing singlet oxygen than earlier photosensitizers, delivering stronger bacterial clearance with shorter laser exposure times.
3. Stable, Easy Storage for Clinics: The trial’s 1% weight/volume Chlorin E6 gel only requires refrigeration between 2°C and 8°C (standard medical fridge temperatures) and cannot freeze, making it simple for hospitals worldwide to stock and transport. The trial uses a fixed dose of 1.0 mg of Ce6 per square centimeter of ulcer surface, a standardized amount that ensures consistent treatment results across all participants.

Beyond killing bacteria, early Phase IIb trial data suggests Ce6-PDT supports healthy tissue regrowth. The light-activated chemical reaction gently stimulates skin repair cells (fibroblasts and keratinocytes) to multiply faster, shrinking ulcer depth and surface area far quicker than standard care alone. This dual benefit—full bacterial eradication plus accelerated wound healing—makes the gel-laser combination unique among current DFU treatments.

Part 3: Inside the Groundbreaking C6-PDT in DFU Clinical Trial
Trial Basics: Who Runs It, Where It Happens, and Timeline
The trial carries the official clinical identifier , nicknamed “C6-PDT in DFU.” It is a single-center, open-label randomized Phase IIb and Phase III study hosted at Creek General Hospital in Karachi, Sindh, Pakistan, led by the United Medical and Dental College as the primary sponsor, with collaboration from Germany’s Synverdis GmbH (Heidelberg) and the Center for Bioequivalence Studies and Clinical Research.

The trial split into two sequential research phases, each designed to answer distinct medical questions:

1. Phase IIb (Fully Completed): Small-scale safety and early efficacy test with 30 enrolled diabetic foot ulcer patients. This stage confirmed the gel-laser treatment caused no severe unexpected side effects and delivered measurable wound shrinkage and bacterial clearance compared to standard care alone.
2. Phase III (Ongoing Recruitment, Target 300 Participants): Large-scale confirmatory research to validate Phase IIb findings on a broader patient group, tracking long-term safety, ulcer recurrence rates, and six-month amputation risk reduction—the study’s most patient-focused secondary goals. Who Can Join the Trial?
   Trial researchers set clear inclusion and exclusion criteria to ensure study participants represent typical DFU patients seen in everyday diabetes clinics, while ruling out anyone who could face safety risks from the gel or laser light. Below is a plain-language breakdown of who qualifies and who cannot enroll: Inclusion Rules (Must Meet All to Participate)
3. Age 18 years or older, male or female, with confirmed diabetes diagnosis.
4. Foot ulcer lasting 4 weeks to 2 years, wound surface size between 0.5 cm² and 20 cm², tissue damage only down to muscle (University of Texas Grade 1A, 1B, 2A, 2B—no exposed bone).
5. Stable blood sugar markers: HbA1c below 12%, random blood sugar under 350 mg/dL.
6. Healthy foot blood flow: Ankle Brachial Index (ABI) between 0.7 and 1.2, ruling out severe artery blockages.
7. No sepsis signs, low sepsis risk score (qSOFA < 2), stable vital signs at screening.
8. Ability to understand trial paperwork, sign voluntary informed consent, and attend all scheduled follow-up visits for up to six months.
9. Only one or two ulcers on the affected leg; ulcers separated by at least 3 cm from each other to avoid overlapping treatment areas. Part 4: What This Trial Means for People Living With Diabetic Foot Ulcers
   Short-Term Patient Benefits If the Treatment Proves Successful
   If Phase III data confirms the positive safety and healing signals seen in the completed Phase IIb stage, Chlorin E6 gel PDT will deliver four immediate, tangible improvements for DFU patients:
10. Faster Wound Closure: Patients could see significant ulcer shrinkage within one week, cutting months of daily dressing changes, pain, and restricted mobility.
11. Full, Reliable Infection Clearance: Unlike antibiotics that fail against biofilm bacteria, PDT eliminates all wound germs in one or two laser sessions, lowering the chance of infection spreading deep into tissue.
12. Less Antibiotic Reliance: Reduced need for long oral antibiotic courses will cut risks of gut disruption, yeast infections, and the rise of drug-resistant bacteria in individual patients and communities.
13. Minimal Side Effects: Topical gel application limits systemic exposure; Phase IIb found only mild, temporary local redness at the ulcer site, no serious organ damage or long-lasting light sensitivity. Long-Term Public Health and Quality-of-Life Impacts
    On a global scale, widely available Ce6-PDT would transform diabetes wound care systems worldwide:

• Sharply Lower Amputation Rates: The trial’s secondary endpoint directly tests whether PDT cuts six-month amputation risk. If successful, thousands of patients each year could avoid permanent limb loss and the steep post-amputation mortality risk.
• Reduced Healthcare Costs: DFUs require frequent hospital stays, specialist visits, expensive dressings, and long-term home nursing support. Faster healing would slash national diabetes healthcare spending and reduce patient financial burden from repeated medical bills.
• Lower Ulcer Recurrence: By fully clearing bacteria and stimulating healthy tissue regeneration, PDT may create stronger, more resilient repaired skin less likely to break open again—a massive relief for patients trapped in a cycle of repeat ulcers.
• Solution for Antibiotic Resistance Crises: As more bacterial strains become untreatable with standard antibiotics, PDT offers a non-chemical infection treatment that works regardless of drug resistance, filling a critical gap in global infectious wound care. Part 5: The Future of Light Therapy for Chronic Wounds
  The Chlorin E6 trial sits at the forefront of a rapidly expanding field of light-based wound medicine. For decades, photodynamic therapy was almost exclusively studied for cancer tumor treatment, using injected photosensitizers and long sun avoidance periods. This trial pioneers a streamlined, topical PDT format designed specifically for everyday chronic skin wounds, clearing the path for similar gel-laser therapies targeting venous leg ulcers, pressure bedsores, and surgical site infections in the coming years.

Researchers also hope this trial’s positive findings will inspire more investment into non-antibiotic infection treatments. Global health organizations rank antibiotic resistance as one of the top ten public health threats facing humanity, and localized PDT offers a sustainable alternative that does not contribute to resistant bacterial evolution. For low- and middle-income countries with limited access to expensive broad-spectrum antibiotics, affordable gel and laser PDT systems could drastically reduce DFU-related hospitalization and amputation disparities.

For individual patients living with the constant stress of a non-healing foot ulcer, this research represents more than a new medical procedure—it represents hope. Many DFU patients report feeling abandoned by standard care that cannot close their wounds, living in constant fear of infection spread and limb loss. A treatment that safely, quickly clears infection and speeds tissue repair could restore mobility, independence, and peace of mind to millions navigating diabetes complications each year.

Conclusion
Diabetic foot ulcers remain an invisible global health crisis, carrying devastating risks of infection, amputation, and shortened lifespans despite routine wound care protocols. The Chlorin E6 gel photodynamic therapy trial () delivers a novel, localized solution that combines a light-activated germ-killing gel with targeted red laser light to address the two biggest flaws of standard DFU treatment: incomplete bacterial clearance and slow tissue regeneration.

The fully completed Phase IIb stage confirmed the therapy’s safety and early healing benefits across 30 participants, while the ongoing Phase III trial with a target enrollment of 300 patients will validate long-term outcomes, including six-month ulcer recurrence and amputation risk reduction. Though the treatment remains in clinical testing and will not be broadly accessible until late 2027, its dual mechanism of erasing drug-resistant wound bacteria and accelerating skin repair marks a revolutionary shift in chronic diabetes wound management.

For anyone living with diabetes, this research underscores two critical takeaways: consistent daily foot self-checks remain the best way to prevent ulcer formation, and medical innovation continues to create gentler, more effective tools to treat wounds once they develop. As trial data unfolds over the next 18 months, Chlorin E6 PDT may soon rewrite clinical guidelines for diabetic foot ulcer care, offering a life-changing light-based therapy to patients who once faced few healing options beyond repeated antibiotics and slow, painful standard wound care.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

---

Related Clinical Trials

Forearm Immobilization in T2D

The aim of the present study is to assess the impact of short-term forearm immobilization on forearm muscle glucose uptake and amino acid net balance and kinetics in individuals with T2D compared with a control group with normoglycaemia.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

Blood glucose management in type 1 diabetes (T1D) remains a challenge, with only \~30% of adults within the recommended consensus guidelines. Novel drugs like glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs have emerged as promising add-ons to insulin in T1D. This application has been designed to test in a prospective study whether adding a new medicine called tirzepatide (GIP/GLP-1RA) to the usual insulin therapy would make a difference for people with T1D in terms of better glucose control.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Ultra-processed Food-reducing Intervention and Continuous Glucose Monitoring

The goal of this trial is to investigate whether reduction in ultra-processed food intake through dietary counseling and education can improve postprandial glucose responses and glycemic variability compared with a usual diet in young, healthy Korean adults aged 20-30 years. The main questions it aims to answer are: \- Does reducing ultra-processed food intake, while maintaining total energy intake and usual lifestyle behaviors, improve postprandial glucose and lower glycemic variability in healthy adults without diabetes? Participants will: * Undergo the 10-day pre-intervention monitoring period, during which each participant will wear a continuous glucose monitoring (CGM) device and concurrently report their daily dietary intakes (all food and beverage consumption) and other lifestyle behaviors (sleep, smoking, physical activity) * After the 10-day pre-intervention monitoring period, participants will be randomized to either intervention or control group * Intervention group: Participants will visit the research site to receive dietitian-led one-on-one nutrition education and personalized dietary counseling targeting reduction of ultra-processed food intake. Personalized diet counseling will be provided by study dietitian based on participant's records of dietary intakes during the 10-day pre-intervention monitoring period. * Control group: Participants will receive dietitian-led nutrition education and personalized dietary counseling based on the national dietary guidelines. * After the intervention, participants will undergo the 10-day post-intervention monitoring period, during which participants will wear a new CGM device for an additional 10 days and continue daily reporting of dietary intakes (all food and beverage consumptions) and lifestyle behaviors (sleep, smoking, physical activity).

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Type 1 Diabetes, Exercise and Mentoring Trial

The proposed study aims to improve the psychosocial health of adolescents living with type 1 diabetes (T1D). The study will generate knowledge and support knowledge mobilization about the effectiveness of a novel model of care for psychosocial health and self-management for adolescents living with type 1 diabetes (T1D). The novel model of care is the recruitment and training if young adult mentors to deliver a behavioural intervention that empowers adolescents with T1D to increase daily physical activity. The study will also advance the development and implementation of this peer mentoring model to improve the psychosocial health of adolescents with T1D.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Continuous Monitoring of Glycemic Variability to Predict Dys- and Hyperglycemia in Asymptomatic Type 1 Diabetes

The goal of this longitudinal clinical trial is to measure variability of interstitial glucose levels with a user-friendly real-time continuous glucose monitoring (CGM) technology at regular intervals in normo- and dysglycemic multiple autoantibody-positive individuals (age 5-39 years), in comparison with single autoantibody-positive individuals in the same age range. Participants will asked to undergo repeated oral glucose tolerance tests (OGTTs) (age 5-39 years) and hyperglycemic clamp tests (age 12-39 years) in parallel for a period of at least 2-3 years. In case of confirmed dysglycemia, we propose to perform CGM and OGTT every 3 months. The main questions the study aims to answer are: 1. Do the amplitude and time trends of CGM-derived glycemic variability indices and OGTT- and clamp-derived variables differ between the intermediate, high and very high risk groups? 2. Can (changes in) CGM-derived glycemic variability indices predict/detect dysglycemia in initially normoglycemic (single or multiple autoantibody-positive) individuals with the same diagnostic efficiency as OGTT- or clamp-derived variables? 3. Can (changes in) CGM-derived glycemic variability indices predict clinical onset in (stage 1 or 2) multiple autoantibody-positive individuals with the same diagnostic efficiency as OGTT- or clamp-derived variables? 4. Can correlating (changes in) CGM-derived indices with (changes in) OGTT- and clamp-derived variables help to better understand the sequence of events leading to dysglycemia and clinical onset, as well as the relative contribution of beta cell function and insulin action to glycemic variability according to disease stage and biological and phenotypical characteristics of the individuals?

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study

The objective of this observational study is to understand the long-term effects of traditional Chinese medicine (TCM) intervention on patients with cerebral infarction onset within \<48 hours and comorbid diabetes. The primary question it aims to address is: Can long-term TCM intervention for the treatment of ischemic cerebrovascular disease comorbid with diabetes improve patients' neurological deficits and self-care ability? Participants receiving TCM intervention (universal treatment combined with syndrome-specific treatment) as part of routine cerebrovascular disease management will undergo follow-up assessments at 30 days, 90 days, 6 months, and 12 months within 1 year to evaluate neurological status (e.g., mRS score, NIHSS score) and quality of life indicators.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Variations in Ketone Metabolism

This outcome of this study will elucidate how the phenotype of the individual modulates the KE metabolic effect. Most studies of KE have been in homogenous populations, usually young, male athletes. However, two striking experiments using identical, body weight adjusted KE doses in healthy and obese individuals found that BHB area under the curve (AUC) and removal was reduced by obesity and poor metabolic health. Similarly, ketone infusion experiments found that diabetes, obesity, and insulin resistance alter BHB metabolism. It is important to determine how obesity affects KE 'sensitivity' (i.e., breakdown and oxidation) because the increasing prevalence of obesity as a function of age. Age may be another important source of variation in ketone metabolism. The genes that control the ketone system are regulated by a cascade of transcription factors and hormones including PPARα and FGF21, which are themselves known to be affected by aging and dietary status, and the cellular protein sensor target of rapamycin (TOR). Aberrant hyperactivation of TOR with aging may reduce ketogenesis, while it was observed that a long-term ketogenic diet specifically up-regulated PPARα activity. Preliminary work revealed substantial changes across mouse lifespan in the expression of ketone-related genes in the liver such as Hmgcs2 (rate limiting for ketone production) and Bdh1 (rate limiting for BHB oxidation) between young, middle-aged, and old mice, with a nadir of gene expression in middle age before increasing again late in life. Substantial age differences were found in response to matched doses of oral KE in mice and in rats. These data may have important implications for treating people of different ages and for translating KE technologies into the Department of VA. Therefore, this project plans to study individual responses to KE ingestion across the lifespan, against the background of varying metabolic health

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes

The overall aim is to investigate the hypothesis that restoring E2 levels through MHT improves glucose and energy homeostasis and potentiates the beneficial effects of GLP-1RA in early postmenopausal women with pre- or existing type 2 diabetes. The primary objective is to assess the efficacy of combined MHT and GLP-1RA in improving glucose control in early postmenopausal women with pre- or existing type 2 diabetes, compared to GLP-1RA alone. Secondary objectives include efficacy analyses on body weight, other measures of cardiometabolic health, lifestyle behaviour, menopausal symptoms, and the exploration of mechanisms underpinning potential glycaemic and weight control benefits, and biomarkers of haemostasis.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Effects of a GLP-1 Formula Drink on Gut Microbiota and Glycemic Control in Prediabetic Individuals

A clinical human dietary intervention trial was conducted to investigate the effects of GLP-1 FORMUL liquid supplementation in individuals with prediabetes or obesity, with a focus on improvements in glycemic and lipid parameters, body composition, and gut microbiota profiles.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Duodenal ReCET for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease

This study is designed to evaluate the efficacy, safety, and mechanisms of ReCET procedure in patients with T2DM and its effect on MASLD.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Evaluation of a Structured Nutrition Educational Program in Insulin-treated Diabetic Patients in Vietnam

The purpose of this study is to find out if learning about healthy eating can help people with diabetes control their blood sugar better. This study is for men and women between 18 and 70 years old who use insulin at least twice a day but still have high blood sugar. We want to answer the following questions: Can nutrition education help lower HbA1c (a blood test that shows average blood sugar over the past 3 months)? Can it improve knowledge about nutrition, quality of life, and make blood sugar more stable? Will it help reduce fasting blood sugar, lipid levels, body weight, and the number of times low blood sugar (hypoglycemia) happens? Participants will be divided into two groups: One group will receive a nutrition booklet. The other group will receive the same booklet and join four monthly lessons with a researcher. The four lessons will talk about: Goals for managing diabetes Main nutrients in food How to plan meals How to eat in a way that supports better blood sugar control

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Impact of Sevoflurane Versus Propofol on Postoperative Delirium in Elderly Diabetic Patients Undergoing Non-Cardiac Surgery: a Multicenter, Randomized Controlled Trial

The present study is a multicenter， randomized controlled clinical trial, which plans to enroll 450 diabetic patients aged more than 60 years. The participants will be randomly assigned in a 1:1 ratio and will receive either propofol or sevoflurane for intraoperative anesthesia maintenance to evaluate the impact of these two anesthetic drugs on postoperative delirium. The aim of our study is to explore whether the use of propofol for anesthesia maintenance in elderly diabetic patients undergoing elective non-cardiac major surgery can reduce the incidence of postoperative delirium. This study will provide new perspectives for improving perioperative management in elderly diabetic patients and optimizing anesthesia management strategies to reduce the risk of postoperative delirium.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Pilot of Food Is Medicine Interventions to Reduce Cardiovascular Disease Risk in Children With Food Insecurity and Diabetes

Study Design: This two-arm parallel trial will randomize 12 families to receive 6-weeks of medically tailored meals or produce prescriptions. Both groups will receive nutrition coaching, weekly during the intervention. The hypothesis is that both interventions to have a positive impact on food security and fruit and vegetable intake. However, medically tailored meals also reduce the logistic barriers of planning, preparing, and calculating the carbohydrate content of nutritionally balanced meals essential for DM management. Therefore, the medically tailored meal intervention will result in greater improvements in the co-primary outcomes of diet quality and glucose stability after the intervention.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Increasing CGM Use Among Patients With T2D

Study Overview: This interventional study aims to assess whether training healthcare professionals (HCPs) increases the number of continuous glucose monitor (CGM) prescriptions for patients with Type 2 Diabetes in a Federally Qualified Health Center serving a predominantly Hispanic/Latino population. Research Questions: Does HCP training enhance CGM prescription rates in a primary care setting? Does receiving a CGM prescription lead to improved Type 2 Diabetes control, as measured by Hemoglobin A1c levels? What barriers do patients face when prescribed and using CGMs? Given the significant impact of CGMs on diabetes management, this project seeks to improve CGM utilization among eligible patients through a focused intervention for HCPs and evaluate diabetes outcomes for those who do and do not receive a CGM. Methodology: HCPs and staff from three clinics within the same healthcare system will undergo a brief, in-person training on current clinical guidelines and insurance eligibility for CGMs. A booster session will follow about one month later to reinforce learning and address any prescribing challenges. Training efficacy will be evaluated by comparing CGM prescription rates before and after training using electronic health records. HCPs will complete pre- and post-training surveys to assess changes in knowledge, beliefs, and prescribing practices related to CGMs. Additionally, a small subset of prescribers will participate in interviews about their experiences with CGM prescriptions four months post-training. Patient Recruitment and Surveys: Patients with Type 2 Diabetes will be recruited for surveys at baseline, and at 3 and 6 months. These surveys will gather information on their diabetes management experience, levels of diabetes distress, and whether CGM discussions occurred with their primary care provider. Participants who received CGM prescriptions will share their experiences and any barriers encountered. A subset will also be invited for interviews to further explore their CGM experiences. Conclusion: This study seeks to fill a crucial gap in understanding how HCP training influences CGM prescription rates and the associated diabetes management outcomes, ultimately aiming to enhance diabetes care for a vulnerable population.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes

This clinical trial aims to evaluate the safety and effectiveness of an intervention involving parental training in behaviour management and medication in children with both Type 1 Diabetes (T1D) and Attention Deficit Disorder with Hyperactivity (ADHD). ADHD is a neurodevelopmental disorder that affects around 5% of school-age children and adolescents, while T1D is a chronic disease requiring strict management. After initial parental training provided for parents/legal guardians, the children will be randomized to one of two cross-over groups, and treated with either lisdexamfetamine or methylphenidate first. After dose optimization for first 5-7 weeks, patients will be treated for 6 months total, after which they will be switched to the other drug. Researchers will then compare the ADHD symptom severity as measured by Conners 3 questionnaire, and compare the frequency of any adverse events associated with the therapy. As secondary outcomes, patient's T1D control and quality of life will be compared between the two drugs.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus

The goal of this clinical trial is to learn if semaglutide can help with weight loss in overweight or obese adults in Bangladesh. The study will also look at how safe semaglutide is for these participants. The main questions to answers are given below: Does semaglutide help participants lose weight after 26 weeks? What changes occur in health measures like blood sugar and quality of life for those taking semaglutide? Participants will: Receive a weekly injection of semaglutide (2.4 mg) for 26 weeks. Follow a plan that includes lifestyle changes, such as diet and physical activity. Have their body weight, waist size, and blood sugar levels measured regularly. This study aims to provide important information on how well semaglutide works for weight loss in Bangladeshi adults, helping to find effective treatments for obesity in this population.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Views on Information Resources for Kidney Transplantation Patients

The goal of this pilot study is to find out whether educational videos can help patients better understand, and remember, important information regarding the benefits and risks of having a kidney transplant. The study aims to answer several questions, including: 1. Is the video-based educational intervention acceptable and feasible for kidney transplant patients? 2. Does the intervention improve patient knowledge and satisfaction immediately after viewing? 3. Does the intervention improve patient knowledge retention a week later? 4. What are patients views on the video format as an educational tool? At the moment, patients learn about kidney transplantation through written documents, and discussions and conversations with their clinicians / doctors. However, the concern here is that not everyone has the same level of understanding when it comes to language literacy, medical jargon and information. This can result in gaps in knowledge, misunderstandings, and / or misinterpretations, including the need for lifelong medication and possible post-transplant complications. Patients understanding of the benefits and risks of transplantation is extremely important, as there are aspects which patients may not be aware of, including the need for (and importance of) lifelong medication, and also potential disease complications which may follow transplantation. For example, following a kidney transplant, it is not uncommon for patients to develop diabetes. Participants in the study will: Watch two short videos (roughly five minutes each) that explain the benefits and risks of kidney transplantation. Answer some questions before video viewing, immediately after video viewing, and one week after video viewing. Complete a short interview to give deeper feedback on the videos. This study will explore whether using video helps patients to feel more informed and also satisfied with the clinical information they receive, and whether they can better retain this information. The investigators aim to support more informed patients, making transplant education clearer, more accessible, and generally easier to understand.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity

The goal of this study is to analyze the effects of enavogliflozin on heart function and coronary microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise capacity in these patients.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Efficacy and Safety of an Artificial Intelligence Tool for Carbohydrate Counting (Tiabete) in Children and Adults With Type 1 Diabetes Mellitus

IntroductionType 1 Diabetes Mellitus (T1DM) requires lifelong exogenous insulin therapy, along with self-management strategies, such as carbohydrate counting, to appropriately adjust insulin doses in response to meals. However, many patients face challenges in adhering consistently to carbohydrate counting, compromising glycemic control and increasing the risk of diabetes-related complications. Emerging technologies, such as artificial intelligence (AI), hold significant potential for optimizing disease management by enhancing the accuracy and efficiency of self-care practices. ObjectiveThe primary aim of this study is to evaluate the efficacy and safety of the AI-based tool Tia Bete, designed to assist patients with T1DM in carbohydrate counting and insulin dose adjustment. The tool provides real-time recommendations based on personalized insulin-to-carbohydrate ratios, insulin sensitivity factors, and individualized glycemic goals. MethodsThis is a prospective, longitudinal study involving 40 patients with T1DM, stratified into two cohorts: 20 children and adolescents (6-18 years) and 20 adults (\>18 years), recruited at the Hospital das Clínicas, University of São Paulo (HCFMUSP). Participants will be assessed before and after six months of using the Tia Bete tool. Glycemic control will be evaluated using parameters such as glycated hemoglobin (HbA1c), time in range, and the incidence of hypoglycemia and hyperglycemia. Quality of life and satisfaction with the tool will also be assessed. Overview of the AI Tool Launched in June 2024, Tia Bete is an AI-based digital solution designed to facilitate glycemic control and improve quality of life for patients with T1DM. By offering real-time assistance with carbohydrate counting and insulin dose recommendations, the tool aims to enhance patient autonomy while enabling flexible treatment adherence in collaboration with their multidisciplinary healthcare team. Results and ConclusionsPreliminary data indicate high engagement, with over 35,000 active users interacting with the platform at least four times per week. Initial findings suggest significant improvements in glycemic control, as well as increased confidence in carbohydrate counting and insulin dose adjustments. The dissemination of this project is crucial for advancing T1DM care, offering a scalable, accessible, and effective technological solution. Final results are expected by October 2025.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info

Automated Insulin for Management of Intrapartum Glycemia

The goal of this clinical trial is learn if automated insulin delivery (AID) systems can be used for glucose management during labor/delivery for pregnant people with type 1 diabetes (T1D). The main questions this study aims to answer are * What are the neonatal glycemic outcomes with use of AID systems during labor/delivery? * Do patients report higher birth satisfaction with use of AID systems during labor/delivery? * Are glycemic parameters like time-in-range (TIR) better with use of AID systems during labor/delivery? Researchers will compare AID systems to intravenous (IV) insulin (the current standard of care for glucose management during labor/delivery) by randomly assigning participants to one or the other.

PDF$29 only! Buy Clinical Trial Full Report With Contact Info